Update on statins: Hope for osteoporotic fracture healing treatment

Current Drug Targets

Volumn 14, Issue 13, 2013, Pages 1524-1532

  Ibrahim, Nurul 'Izzah ^a   Mohamed, Norazlina ^a   Shuid, Ahmad Nazrun ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

BMP 2; Fracture healing; HMG COA reductase inhibitor; Osteoporosis; VEGF

Indexed keywords

ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CYTOCHROME P450; ESTROGEN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VASCULOTROPIN; VASCULOTROPIN A;

APOPTOSIS; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BREAST CANCER; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE HEALING; FRAGILITY FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; LIVER FAILURE; LOW DRUG DOSE; META ANALYSIS (TOPIC); NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVARY CANCER; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN PRENYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); TISSUE DIFFERENTIATION; ANIMAL; BONE; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEIN 2; CLINICAL TRIALS AS TOPIC; FEMALE; FRACTURE HEALING; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84888984845     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990195     Document Type: Article

References (107)

1. Richard D, Wasnich MD. Epidemiology of osteoporosis. In: Primer in the metabolic bone diseases and disorders of mineral metabolism; Flavus MJ, Ed., 3rd Ed. New York: Lipincott-Raven, 1996; pp 249-251.
2. Grundnes O, Reikeras O. The importance of the hematoma for fracture healing in rats. Acta Orthop Scand 1993; 64: 340-2.
3. Cruess RL, Dumont J. Healing of bone, tendon, and ligament in Fractures, In: Textbook of Small Animal Orthopaedics, Newton CD and Nunamaker DM (Eds). International Veterinary Information Service (www.ivis.org), Ithaca, New York, USA. 1975; pp 127.
4. Einhorn TA. Enhancement of fracture-healing. J Bone Joint Surg Am 1995; 77(6): 940-56.
5. Hauser CJ, Zhou X, Joshi P, et al. The immune microenvironment of human fracture/soft-tissue hematomas and its relationship to systemic immunity. J Trauma 1997; 42: 895-903.
6. Hausman MR, Schaffler, MB, Majeska RJ. Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 2001; 29: 560-4.
7. Einhorn TA. The cell and molecular biology of fracture healing. Clin Orthop 1998; 355(Suppl.): S7-21.
8. Gerstenfeld LC, Cullinane DM, Barnes GL, Graves DT, Einhorn TA. Fracture healing as a postnatal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 2003; 88: 873-84.
9. Hadjiargyrou M, Lombardo F, Zhao S, et al. Transcriptional profiling of bone regeneration. Insight into the molecular complexity of wound repair. J Biol 2002; 277: 30177-82.
10. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 1997; 103(3S-8S) discussion 8S-11S.
11. Dai K, Hao Y. Quality of healing compared between osteoporotic fracture and normal traumatic fracture, In: Advanced Bioimaging Technologies in Assessment of the Quality of Bone and Scaffold Materials Techniques and Applications; Qin L, Genant HK, Griffith JF and Leung KS (Eds) Berlin, Germany, Springer, 2007; 531-41.
12. rd. Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 1992; 2(6): 285-9.
13. International Osteoporosis Foundation (IOF), 2010. High death and disability rates due to Osteoporotic fractures in Russia, Central Asia and Eastern Europe. International Osteoporosis Foundation. http://www.iofbonehealth.org/news/newsdetail.html?newsID=362.
14. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002; 17: 2237-46.
15. Danielsen CC, Mosekilde L, Svenstrup B. Cortical bone mass, composition, and mechanical properties in female rats in relation to age, long-term ovariectomy, and estrogen substitution. Calcif Tissue Int 1993; 52(1): 26-33.
16. Peng Z, Tuukkanen J, Zhang H, et al. The mechanical strength of bone in different rat models of experimental osteoporosis. Bone 1994; 15: 523-32.
17. Aerssens J, Audekercke R, Talalaj M, et al. Effect of 1-Vitamin D3 and Estrogen therapy on cortical bone mechanical properties in the ovariectomized rat model. Endocrinology 1996; 137: 1358-64.
18. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129.
19. European Foundation for Osteoporosis and Bone Disease (EFFO) and National Osteoporosis Foundation of the USA (NOF). Who are candidates for prevention and treatment for osteoporosis? Osteoporosis International 1997; 7(1): 1-6.
20. Loh KY, Shong HK. Osteoporosis: primary prevention in the community. Medical Journal of Malaysia 2007; 62(4): 355-7.
21. Lauralee S. Fundamentals of Physiology: A Human Perspective, 4th edition, Canada, Brooks/Coe Cengage Learning 2011.
22. Arjmandi BH, Alekel L, Hollis BW, et al. Dietary soybean protein prevents bone loss in an ovarectomized rat model of osteoporosis. J Nutr 1996; 126(1): 161-7.
23. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286: 2815-22.
24. Mundy GR. Osteoporosis into the year 2010. Br J Obstet Gynaecol 1996; 103(suppl. 13): 32-7.
25. Gambacciani M, Ciaponi M. Postmenopausal osteoporosis management. Curr Opin Obstet Gynecol 2000; 12(3): 189-97.
26. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288(3): 321-33.
27. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA 2003; 289(24): 3243-53.
28. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women-the women's health initiative memory study: a randomized controlled trial. JAMA 2003; 289(20): 265-162.
29. Nochowitz B, Siegert S, Wasik M. An Update on Osteoporosis. American Journal of Therapeutics. 2009; 16: 437-45.
30. Zhou S, Fang X, Xin H, Guan S. Effects of alendronate on the Notch1-RBP-J signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells. Mol Med Rep 2013; 8: 89-94.
31. Murphy FT, Kivitz AJ, Sands EE. Management of postmenopausal osteoporosis. JAOA 2003; 103: S6-S11.
32. McAdam-Marx C, LaFleur J, Kirkness C, Asche C. Postmenopausal osteoporosis Current and Future Treatment Options. P&T Journal 2007; 32: 392-402.
33. Papapoulos S. Controversial issues with biphosphonate treatment. Endocrine Abstracts 2012; 29: S28.1
34. Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporos Int 1990; 1(1): 7-13.
35. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators of action and application to clinical practice. N Engl J Med 2003; 348: 618-29.
36. Margolis RN, Canalis E, Partridge NC. Invited review of a workshop: anabolic hormones in bone: basic research and therapeutic potential. J Clin Endocrinol Metab 1996; 81(3): 872-7.
37. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
38. Hwang R, Lee EJ, Kim MH, et al. Calcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatin on bone. J Biol Chem 2004; 279(20): 21239-47.
39. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001; 29: 176-9.
40. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87: 2060-6.
41. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357: 905-16.
42. Whitfield JF. How to grow bone to treat osteoporosis and mend fractures. Curr Rheumatol Rep 2003; 5: 45-56.
43. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of Fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-9.
44. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-9.
45. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
46. Schacter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2004; 19: 117-25.
47. Bottroff M, Hansten P. Long-term safety of hepatic hydroxylmethyl glutaryl coenzyme A reductase inhibitors:the role of metabolism-monograph for physicians. Arch Intern Med 2000; 279: 2273-80.
48. Schacter M. Statins, drug interactions and cytochrome P450. Br J Cardiol 2001; 8: 311-7.
49. Fujino H, Yamada I, Kojima J, et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human. Xeno Metab Disp 1999; 14: 415-24.
50. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000; 271: 688-92.
51. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39: 397-412.
52. Horiuchi N, Maeda T. Statins and bone metabolism. Oral diseases 2006; 12: 85-101.
53. Burridge K, Chrzanowska WM. Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 1996; 12: 463-518.
54. Zigmond SH. Signal transduction and actin filament organization. Curr Opin Cell Biol 1996; 8: 66-73.
55. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000; 15: 1467-76.
56. Van Beek E, Lowik C, van der Pluijm G, et al. The role of geranylgeranylation in bone resorption and its suppression by bisphosphoates in fetal bone explants In vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999; 14: 722-9.
57. Hagihara M, Endo M, Hata K, et al. Neogenin, a Receptor for Bone Morphogenetic Proteins. J Biol Chem 2011; 286(7): 5157-65.
58. Ohnaka K, Shimoda S, Nawata H, et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 2001; 287(2): 337-42.
59. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006; 290: C661-C668.
60. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998; 16: 247-52.
61. Kretzschmar M, and Massague J. SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 1998; 8: 103-11.
62. Ogasawara T, Kawaguchi H, Jinno S, et al. Bone Morphogenetic Protein 2-Induced Osteoblast Differentiation Requires SmadMediated Down-Regulation of Cdk6. Mol Cell Biol 2004; 24: 6560-8.
63. Kureishi Y, Luo Z, Shiojimo I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6(9): 1004-10.
64. Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 2003; 144: 681-92.
65. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
66. Deckers MML, Karperien M, van der Bent C, et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 2000; 141(5): 1667-74.
67. Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption, J Exp Med 1999; 190: 293-98.
68. Wang DS, Miura M, Demura H, et al. Anabolic effects of 1,25dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Endocrinology 1997; 138: 2953-62.
69. Zelzer E, McLean W, Ng YS, et al. Skeletal defects in VEGF (120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 2002; 129: 1893-904.
70. Hiltunen MO, Ruuskanen M, Huuskonen J, et al. Adenovirusmediated VEGF-A gene transfer induces bone formation in vivo. FASEB J 2003; 17: 1147-9.
71. Ferguson C, Alpern E, Miclau T, et al. Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev 1999; 87: 57-66.
72. Tatsuyama K, Maezawa Y, Bab H, et al. Expression of various growth factors for cell proliferation and cytodifferentiation during fracture repair of bone. Eur J Histochem 2000; 44(3): 269-78.
73. Vico L. VEGF and bone formation: New perspectives. Eur Cells Mat 2007; 14(1): 32.
74. Street J, Winter D, Wang JH, Wakai A, McGuinness A, Redmond HP. Is human fracture hematoma inherently angiogenic? Clin Orthop 2000; 224-37.
75. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5: 623-8.
76. Street J, Bao M, deGuzman L, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 2002; 99: 9656-61.
77. Bostrom MP. Expression of bone morphogenetic proteins in fracture healing. Clin Orthop Relat Res 1998; 355: S116-23.
78. Wang EA, Israel DI, Kelly S, Luxenberg DP. Bone morphogenetic protein-2 causes commitment and differentiation in C3h10T1/2 and 3T3 cells. Growth Factors 1993; 9(1): 57-71.
79. Ahrens M, Ankenbauer T, Schroder D, Hollnagel A, Mayer H, Gross G. Expression of human bone morphogenetic proteins-2 or4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biol 1993; 12: 871-80.
80. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. 1997; 89: 755-64.
81. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-71.
82. Gutierrez GE, Edwards JR, Garrett IR, et al. Transdermal lovastatin enhances fracture repair in rats. JBMR 2008; 23(11): 1722-30.
83. Maritz FJ, Conradie MM, Hulley PA, et al. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001; 21: 1636-41.
84. Mostaza JM, De la Piedra C, Curiel MD, et al. Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-manopausal women. Clin Chim Acta 2001; 308: 133-7.
85. Reinoso RF, Sanchez Navarro A, Garcia MJ, et al. Preclinical pharmacokinetic of statins. Methods Find Exp Clin Pharmacol 2002; 24: 593-613.
86. Abdul-Majeed S, Mohamed N, Soelaiman IN. Effects of Tocotrienol and Lovastatin Combination on Osteoblast and Osteoclast Activity in Estrogen-Deficient Osteoporosis. Evid Based Complement Alternat Med 2012; 2012: 1-9.
87. Skoglund B, Forslund C, Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res 2002; 17: 2004-8.
88. Guyton JR. Benefit versus risk in statin treatment. Am J Cardiol 2006; 97(8A): 95C 97C.
89. Wang JW, Xu SW, Yang DS, et al. Locally applied simvastatin promotes fracture heling in ovariectomized rat. Osteoporosis Int 2007; 18: 1641-50.
90. Garrett IR, Gutierrez GE, Rossini G, et al. Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J Orthop Res 2007; 25: 1351-7.
91. Nyman JS, Munoz S, Jadhav S, et al. Quantitative measures of femoral fracture repair in rats derived by micro-computed tomography. J Biomech 2009; 42: 891-7.
92. Shokri N, Akbari Javar H, Fouladdel Sh, et al. Preparation and evaluation of poly(caprolactone fumurate)nanoparticles containing Doxorubicin Hcl. DARU Journal of Pharmaceutical Sciences 2011; 19(1): 12-22. Retrieved from http://daru.tums.ac.ir/index.php/daru/article/view/521/517.
93. Hazem A, Amit Shirode B, Sylvester PW, et al. Preparation, characterization and anticancer effects of simvastatin-tocotrienol lipid nanoparticles. Int J Pharm 2010; 389: 223-31.
94. Peer D, Karp JC, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2: 751-60.
95. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG CoA reductase inhibitors and risk of fracture. JAMA 2000; 283(24): 3205-10.
96. Ray WA, Daughtery JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 2002; 8: 276-279.
97. Reddi AH, Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat. Biotechnol 1998; 16: 247-52.
98. Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85: 1137-42.
99. Bauer SDC, Mundy GR, Jamal SA, et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone miner Res 1999; 14: S179.
100. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin Use, Bone Mineral Density, and Fracture Risk. Arch Intern Med 2002; 162: 537-40.
101. Chan KA, Andrade SE, Boles M, et al. Inhibitors of Hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185-88.
102. Bauer DC, Mundy GR, Jamal SA, et al. Use of Statins and Fracture. Arch Intern Med 2004; 164: 146-52.
103. Patil S, Holt G, Raby N, et al. Prospective,double blind, randomized,controlled trial of simvastatin in fracture healing. J Orthop Res 2009; 27(3): 281-5.
104. Van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285: 1850-5.
105. Yue J, Zhang X, Dong B, et al. Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause 2010; 17(5): 1071-9.
106. LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture and bone density in postmenopausal women: Results from the Women's Health Initiative Study. Arch Intern Med 2003; 139: 97-104.
107. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret G. Effects of statins on bone mineral density: A meta-analysis of clinical studies. Bone 2007; 40: 1581-7.